ClinicalTrials.gg
CompletedNCT00685815RLSUpdated May 6, 2025Results posted

Intravenous Iron Metabolism in Restless Legs Syndrome

A Phase 2 interventional study of Ferric Carboxymaltose (FCM) and Placebo in Restless Legs, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.

Enrollment
81st of 95
12 · median 46
Started
2006
with 5 others
Phase 2
16 of 107
1 open now
Registered
31st of 107
by date
Lead sponsor
3 of 107
American Regent, Inc.

Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 81st largest by enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2006, is one of 16 in phase 2, and was the 31st registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Restless Legs Syndrome with a site in United States, or all of them as a file.
02

Study summary

Double-blind, placebo-controlled, entitled: "Intravenous Iron Metabolism in Restless Legs Syndrome

Read the detailed description

To determine the effects of high-dose infusions of iron on Restless Legs Syndrome (RLS) symptoms and brain concentrations of iron.

03

Conditions studied

  • Restless Legs

Keywords

  • IV Iron
  • Restless Legs Syndrome
  • RLS
  • Iron
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Restless Legs Syndrome (RLS).
  • Presence of increased periodic leg movements of sleep (PLMS) before receiving treatment.
  • Patient sleep times are between 9pm and 9am.
  • Patient's RLS symptoms would occur daily if you were not on medication.

Exclusion criteria

Exclusion Criteria:

  • RLS secondary to other medical disorders as determined by history and physical/neurological examination.
  • On a treatment (e.g., psychiatric medication) that might significantly alter RLS symptoms or study results and who cannot discontinue medication for the extended period of the study.
  • History of multiple adverse drug reactions or specifically an allergy to IV iron.
  • Currently experiencing a serious medical condition (chronic organ failure, active inflammation or infection, congestive heart failure, etc.) that might alter iron metabolism, would place them at risk, or interfere with study participation.
  • An magnetic resonance imaging (MRI) is not possible because of medical reasons (Pacemaker; loose iron in the tissue) or concern about severe claustrophobia.
  • Any condition that is likely to increase iron loss (chronic bleeding, excluding menstruation; medically necessary phlebotomy) or consumption (pregnancy).
  • Serum ferritin >300mg/L or percent iron saturation >50%. This is to exclude subjects with probable hemochromatosis.
  • Significant medical (e.g., inflammatory bowel syndrome; bowel dysmotility syndromes) or surgical (e.g., gastrojejunal bypass, colectomy) GI tract problems; and active chronic inflammatory processes (e.g., active hepatitis, rheumatoid arthritis, systemic lupus erythematosus). This is to exclude conditions which will potentially alter iron metabolism.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Ferric carboxymaltose (FCM)

    Intravenous iron (FCM)

    Drug: Ferric Carboxymaltose (FCM)

  • Placebo comparator
    Placebo

    normal saline

    Drug: Placebo

Interventions

  • 500mg FCM in 250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4

    Also known as: Injectafer

  • DrugPlacebo

    250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4

06

What researchers measure

Primary outcomes

  1. Duration Off Treatment

    Number of weeks that patients were able to remain off treatment for RLS

    Time frame: 2 weeks, 4 weeks, and 52 weeks

07

Results

Posted May 6, 2025

Participant flow

Participant flow — Overall Study
MilestoneFerric Carboxymaltose (FCM)Placebo
Started84
Completed84
Not completed00

Outcome measures

PrimaryDuration Off Treatment

Number of weeks that patients were able to remain off treatment for RLS

Time frame:
2 weeks, 4 weeks, and 52 weeks
Reported as:
Number · participants
Duration Off Treatment
participantsFerric Carboxymaltose (FCM)Placebo
Duration - 2 weeks63
Duration - 20 weeks20
Duration - 52 weeks01

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose (FCM)0/8 (0%)0/8 (0%)0/8 (0%)
Placebo0/4 (0%)0/4 (0%)0/4 (0%)

Baseline characteristics

Intent to Treat Population

Age, Customized
Age, Customized(Participants)Ferric Carboxymaltose (FCM)PlaceboTotal
< 25 years437
25 - 50 years213
> 50 years202
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM)PlaceboTotal
Female415
Male437
08

Study locations

1 site
  • The Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Dec 2010 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2025, 14 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2008
First posted
May 28, 2008
Start
Nov 2006
Primary completionActual
Dec 2010
CompletionActual
Dec 2012
Results first posted
May 6, 2025
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00685815
Responsible party
Sponsor
First posted
May 28, 2008
Start date
Nov 2006
Primary completion
Dec 2010
Completion
Dec 2012
Results posted
May 6, 2025
Last update
May 6, 2025

Study contacts

Christopher J. Earley, MD, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion